Trastuzumab-resistant breast cancer cells remain sensitive to the auger electron-emitting radiotherapeutic agent 111In-NLS-trastuzumab and are radiosensitized by methotrexate

Journal of Nuclear Medicine

Volumn 49, Issue 9, 2008, Pages 1498-1505

  Costantini, Danny L ^a   Bateman, Katherine ^a   McLarty, Kristin ^a   Vallis, Katherine A ^b   Reilly, Raymond M ^a,c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Auger electrons; Breast cancer; Methotrexate; Radiosensitization; Trastuzumab (Herceptin)

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN G; INDIUM 111; METHOTREXATE; PENTETIC ACID; TRASTUZUMAB;

ARTICLE; AUGER ELECTRON SPECTROSCOPY; BINDING ASSAY; BREAST CANCER; CANCER CELL; CANCER SURVIVAL; CELL FRACTIONATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DOSE RESPONSE; DRUG CONJUGATION; DRUG UPTAKE; HUMAN; HUMAN CELL; NUCLEAR IMPORT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOASSAY; RADIOIMMUNOTHERAPY; RADIOSENSITIZATION; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; HUMANS; INDIUM RADIOISOTOPES; METHOTREXATE; NUCLEAR LOCALIZATION SIGNALS; RADIATION-SENSITIZING AGENTS; RADIOPHARMACEUTICALS;

EID: 51349121953     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.051771     Document Type: Article

References (37)

1. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
2. Konecny G, Pauletti G, Pegram M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst. 2003;95:142-153.
3. Kolar Z, Murray PG, Zapletalova J. Expression of c-erbB-2 in node negative breast cancer does not correlate with estrogen receptor status, predictors of hormone responsiveness, or PCNA expression. Neoplasma. 2002;49:110-113.
4. Love RR, Duc NB, Havighurst TC, et al. Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol. 2003;21:453-457.
5. Nahta R, Hortobagyi GN, Esteva FJ. Growth factor receptors in breast cancer: potential for therapeutic intervention. Oncologist. 2003;8:5-17.
6. Wolff AC, Hammond EH, Schwartz JN, Hagerty KI, American DCA. Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145.
7. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719-726.
8. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639-2648.
9. 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts. J Nucl Med. 2003;44:1469-1478.
10. 111In in human myeloid leukemia cells. J Nucl Med. 2006;47:827-836.
11. 111In- labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J Nucl Med. 2007;48:1357-1368.
12. O'Donoghue JA, Wheldon TE. Targeted radiotherapy using Auger electron emitters. Phys Med Biol. 1996;41:1973-1992.
13. Boswell CA, Brechbiel MW. Auger electrons: lethal, low energy, and coming soon to a tumor cell nucleus near you. J Nucl Med. 2005;46:1946-1947.
14. Costantini DL, Hu M, Reilly RM. Peptide motifs for insertion of radiolabeled biomolecules into cells and routing to the nucleus for cancer imaging or radiotherapeutic applications. Cancer Biother Radiopharm. 2008;23:3-24.
15. DeNardo SJ, Denardo GL. Targeted radionuclide therapy for solid tumors: an overview. Int J Radiat Oncol Biol Phys. 2006;66(suppl):S89-S95.
16. Wong JY. Systemic targeted radionuclide therapy: potential new areas. Int J Radiat Oncol Biol Phys. 2006;66(2 suppl):S74-S82.
17. Spittle MF. Methotrexate and radiation. Int J Radiat Oncol Biol Phys. 1978;4:103-107.
18. Allen BG, Johnson M, Marsh AE, Dornfeld KJ. Base excision repair of both uracil and oxidatively damaged bases contribute to thymidine deprivation-induced radiosensitization. Int J Radiat Oncol Biol Phys. 2006;65:1544-1552.
19. Lawrence TS, Blackstock AW, McGinn C. The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin Radiat Oncol. 2003;13:13-21.
20. du Manoir JM, Francia G, Man S, et al. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin Cancer Res. 2006;12:904-916.
21. Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA. 1992;89:4285-4289.
22. Hu M, Chen P, Wang J, Chan C, Scollard DA, Reilly RM. Site-specific conjugation of HIV-1 tat peptides to IgG: a potential route to construct radio-immunoconjugates for targeting intracellular and nuclear epitopes in cancer. Eur J Nucl Med Mol Imaging. 2006;33:301-310.
23. Li JC, Kaminskas E. Accumulation of DNA strand breaks and methotrexate cytotoxicity. Proc Natl Acad Sci USA. 1984;81:5694-5698.
24. Lawrence TS, Chang EY, Hahn TM, Hertel LW, Shewach DS. Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′- deoxycytidine. Int J Radiat Oncol Biol Phys. 1996;34:867-872.
25. Cho HS, Mason K, Ramyar KX, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 2003;421:756-760.
26. Worm J, Kirkin AF, Dzhandzhugazyan KN, Guldberg P. Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate- resistant human breast cancer cells. J Biol Chem. 2001;276:39990-40000.
27. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol. 2007;18:977-984.
28. Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004;6:117-127.
29. kip1 down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res. 2004;64:3981-3986.
30. Ritter CA, Perez-Torres M, Rinehart C, et al. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res. 2007;13:4909-4919.
31. Lu Y, Zi X, Pollak M. Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int J Cancer. 2004;108:334-341.
32. Yu D, Liu B, Jing T, et al. Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. Oncogene. 1998;16:2087-2094.
33. 111In-anti-CD33 monoclonal antibodies modified with nuclear localizing peptide sequences. J Nucl Med. 2008;49:1546-1554.
34. Orlando L, Cardillo A, Ghisini R, et al. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer. 2006;6:225.
35. Shewach DS, Lawrence TS. Antimetabolite radiosensitizers. J Clin Oncol. 2007;25:4043-4050.
36. 125I]iodo-2′-deoxyuridine and methotrexate in the treatment of advanced neoplastic meningitis. Int J Radiat Biol. 2004;80:941-946.
37. Pegram M, Ngo D. Application and potential limitations of animal models utilized in the development of trastuzumab (Herceptin): a case study. Adv Drug Deliv Rev. 2006;58:723-734.